Journal List > J Korean Diabetes Assoc > v.30(4) > 1062390

TOOLS
Choi, Kim, Kim, Kim, Nam, Park, Shon, Ahn, Lee, Lee, Lee, Chung, Cha, and 83 investigators: Efficacy Evaluation of Atorvastatin in Korean Hyperlipidemic Patients with Type 2 Diabetes Mellitus
Original Article
The Journal of Korean Diabetes Association

The Journal of Korean Diabetes Association 2006; 30(4): 292-302.

Published online: 31 July 2006

DOI: https://doi.org/10.4093/jkda.2006.30.4.292

Efficacy Evaluation of Atorvastatin in Korean Hyperlipidemic Patients with Type 2 Diabetes Mellitus

Dong-Seop Choi1, Duk-Kyu Kim2, Doo-Man Kim3, Seong-Yeon Kim4, Moon-Suk Nam5, Yong-Soo Park6, Ho-Sang Shon7, Chul-Woo Ahn8, Kwan-Woo Lee9, Ki-Up Lee10, Moon-Kyu Lee11, Choon-Hee Chung12, Bong-Yeon Cha13; 83 investigators

1Department of Endocrinology & Metabolism, College of Medicine Korea University, Korea.

2Department of Endocrinology, Dong-A University Medical Center, Korea.

3Department of Endocrinology, Kangdong Sacred Heart Hospital, Korea.

4Division of Endocrinology and Metabolism, Seoul National University Hospital, Korea.

5Department of Endocrinology, Inha University Hospital, Korea.

6Department of Endocrinology, Hanyang University Guri Hospital, Korea.

7Department of Endocrinology, Daegu Catholic University of Daegu, School of Medicine, Korea.

8Department of Endocrinology, Yongdong Severance Hospital, Korea.

9Department of Endocrinology and Metabolism, Ajou University Hospital, Korea.

10Department of Endocrinology, Asan Medical Center, Korea.

11Department of Endocrinology and Metabolism, Samsung Medical Center, Korea.

12Department of Endocrinology, Yonsei University Wonju Christian Hospital, Korea.

13Department of Endocrinology & Metabolism, College of Medicine the Catholic University of Korea, Korea.

Received 24 April 2006       Accepted 5 July 2006

Copyright © 2006 Korean Diabetes Association

Abstract

Background

NCEP ATP III Guideline recommends aggressive treatments of diabetic dyslipidemia, recognizing diabetes mellitus as CHD risk equivalents. This study was conducted to evaluate the effectiveness and safety of atorvastatin in hyperlipidemic patients with Type 2 diabetes mellitus through post-marketing drug use investigation of atorvastatin.

Methods

An open, multi-center, non-comparison, titrated dosage study was conducted in hyperlipidemic patients, who were treated with atorvastatin at first visiting hospitals from Mar. 2004 to Sep. 2004. 96 endocrinologists participated from 66 centers in this study. Total 2,182 hyperlipidemic patients were enrolled and 1,514 patients among them were accompanied by diabetes mellitus. Efficacy was evaluated at later than 4-week treatment by % change of total cholesterol, triglycerides, HDL-cholesterol and LDL-cholesterol from baseline. Percent of patients reaching LDL-cholesterol level less than 100 mg/dL was also analyzed. The adverse events incidence and abnormalities of clinical laboratory values were evaluated for safety monitoring.

Results

Total cholesterol, triglycerides, and LDL-cholesterol level were reduced by 26.6%, 12.0%, and 34.8%, respectively, in diabetic hyperlipidemic patients after atorvastatin treatment. The patients with LDL-cholesterol level of less than 100 mg/dL were increased from 2.8% to 52.6%. Atorvastatin was considered to be safe because adverse drug reactions were reported in 32 patients (1.5%) of total 2,182 patients.

Conclusion

Atorvastatin was effective and safe in hyperlipidemic patients with type 2 diabetes mellitus.

Keywords: Atorvastatin, Hyperlipidemia, LDL-cholesterol, Total cholesterol, Type 2 diabetes mellitus

Figures and Tables

Table 1
Baseline Characteristics of Enrolled Patients
jkda-30-292-i001
Table 2
Blood Pressure in Hyperlipidemic Patients with Diabetes Mellitus
jkda-30-292-i002
Table 3
Changes in Lipid Profile after Atorvastatin Treatment in Hyperlipidemic Patients
jkda-30-292-i003
Table 4
Changes in Lipid Profile after Atorvastatin Treatment in Hyperlipidemic Patients with Type 2 Diabetes Mellitus
jkda-30-292-i004
Table 5
Distribution of LDL-C Levels in Hyperlipidemic Patients with Diabetes Mellitus (%)
jkda-30-292-i005
Table 6
Changes in Glucose Level and HbA1C Level in Hyperlipidemic Patients with Diabetes Mellitus
jkda-30-292-i006
Table 7
Incidence of Adverse Drug Reactions by Body System in Total Hyperlipidemic Patients and DM-Complicated Hyperlipidemic Patients
jkda-30-292-i007

References

1. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norolae S, Pastrenack A, Pikkareinen J, Romo M, Sjoblom T, Nikkila EA. Helsinki heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987. 317:1237–1245.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995. 333:1301–1307.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993. 16:434–444.
4. Ho JE, Paultre F, Mosca L. Is diabetes mellitus a cardiovascular diseases risk equivalent for fatal stroke in women? Data from the Women's Pooling Project. Stroke. 2003. 34:2812–2816.
5. McCarron P, Greenwood R, Elwood P, Shlomo YB, Bayer I, Frankel S, Ebrahim S, Murray L, Smith GD. The incidence and aetiology of stroke in the Caerphilly and Speedwell Collaborative Studies II: risk factors for ischemic stroke. Public Health. 2001. 115:12–20.
6. American Diabetes Association. Position Statement: Management of dyslipidemia in adults with diabetes. Diabetes Care. 2002. 25:S74–S77.
7. American Diabetes Association. Position Statement: Management of dyslipidemia in adults with diabetes. Diabetes Care. 2001. 24:S58–S61.
8. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994. 89:1333–1445.
9. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001. 285:2486–2497.
10. Waters D. Statins and Safety: Applying the results of randomized trials to clinical practice. Am J Cardiol. 2003. 92(6):692–695.
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Johns DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA. 2003. 289:2560–2572.
14. Jones PH, McKenney JM, Karalis DG, Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J. 2005. 149:111e1–e111. e8
15. Grundy SM, Cleeman JI, Merz NB, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004. 110:227–239.
16. Olsson AG, Eriksson M, Johnson O, Kjellstrm T, Lanke J, Larsen ML, Pedersen T, Tikkanen MJ, Wiklund O. 3T study investigators. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: The treat-to-target study. Clin Ther. 2003. 25:119–138.
TOOLS
Similar articles